Worthington Biochemical Corporation Announces Expansion of GMP Compliant Enzyme Offering via Strategic Agreement with Cytori Therapeutics

Worthington has announced distribution rights to the Celase® GMP compliant enzyme from Cytori Therapeutics, San Diego, CA. The new Celase® GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.

Celase® GMP is a proprietary enzyme containing a unique blend of collagenase, neutral protease and buffer salts that are produced using avian and mammalian tissue-free raw materials, aseptically processed, sterile filtered and highly purified under GMP guidelines. A single, sterile, ready to use enzyme containing both collagenase and a neutral protease is ideal for a wide range of adipose stem cell, biomedical and bioprocessing applications.

“We are excited to offer Cytori’s Celase® GMP product to Worthington’s Collagenase and STEMxyme® portfolio for biomedical research and related bioprocessing applications. It was very important for us to find an enzyme that meets our stringent requirements for high quality and reproducible performance,” said Von Worthington, President and CEO at Worthington Biochemical Corporation. “This new Celase® GMP product offering will be marketed through our catalog, direct sales force, distributor network, e-commerce website and upcoming scientific meetings.”

Cytori Therapeutics’ extensive product development expertise yields a best-in-class enzyme formulation providing researchers with superior and unparalleled convenience in their lab, clarity in their approach, and confidence in their results.

“We are very excited and pleased to initiate a partnership for Celase® GMP with a respected enzyme manufactured like Worthington which has decades of experience successfully serving the biomedical research and technology field,” said Russ Havranek, Director of Marketing at Cytori Therapeutics.